Gilead Sciences (GILD): Evaluating Valuation as Shares Trend Higher in 2024

Gilead Sciences (GILD) has seen some movement in its stock price recently, drawing interest from investors tracking the pharmaceutical sector. Shares have climbed 5% over the past month and gained 3% in the past 3 months.

See our latest analysis for Gilead Sciences.

While Gilead's shares have ticked upward in the short term, the real story has been its overall momentum, thanks to a 28.3% year-to-date share price return and an impressive 37.8% total shareholder return over the past year. These gains reflect growing confidence in both the company's pipeline and its ability to deliver for long-term investors.

If pharma's resilience has you looking for other potential leaders, there's a lot more to discover in our curated list of standout healthcare stocks in See the full list for free.

With shares trending higher, the key question is whether Gilead Sciences remains undervalued based on its fundamentals, or if the market has already priced in all the optimism about its future growth prospects.

Most Popular Narrative: 7.4% Undervalued

Gilead Sciences is trading at $117.88, and the most widely followed narrative suggests the fair value is $127.23. Investors are watching whether this modest discount signals the beginning of a larger trend.

The launch and scaling of innovative products (Yeztugo, Trodelvy first-line, Livdelzi) position Gilead to deliver a more favorable product mix and premium pricing. This could drive higher gross margins and improve the long-term earnings trajectory as portfolio diversification reduces overexposure to legacy products.

Read the complete narrative.

How is this fair value justified? The narrative is built on optimism for next-generation products, stronger profit margins, and ambitious revenue goals. Interested in the future growth assumptions supporting these projections? Only the full story reveals the critical factors that inform this price estimate.

Result: Fair Value of $127.23 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, potential regulatory changes or setbacks in Gilead’s innovation pipeline could quickly temper the optimism that supports the current growth narrative.

Find out about the key risks to this Gilead Sciences narrative.

Build Your Own Gilead Sciences Narrative

If you have a different take or want to see how your perspective stacks up, you can craft your own Gilead Sciences narrative in just a few clicks. Do it your way.

A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Smart investors go beyond the obvious. Don’t miss your chance to uncover hidden gems and future leaders using the Simply Wall Street Screener today.

• Capture growth with these 26 AI penny stocks, which are harnessing artificial intelligence to redefine industries and unlock new levels of innovation.
• Target reliable income by reviewing these 19 dividend stocks with yields > 3%, highlighting companies with attractive yields and healthy dividend track records.
• Position yourself for market shifts by examining these 80 cryptocurrency and blockchain stocks, where blockchain and crypto pioneers are reshaping digital finance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com